PharmaBoardroom

Biosimilars Work. Why Aren’t They Taking Off in the US?

The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save…

Beyond Generics: Dr Reddy’s Going Global

Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a…

Kevin Pan – CEO, Asieris, China

Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific…

Tomas Blomquist – CEO, Biotage, Sweden

Biotage, a Swedish company that specializes in separation technology, from analysis to industrial scale, and high-quality solutions for organic and…

Irwin Wang – CEO, Reistone Biopharma, China

Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration…

Debbie Hart – Founding President & CEO, BioNJ, USA

BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New…

Simon Björklund – CEO, Bioglan, Sweden

Simon Björklund, CEO of Bioglan, a Swedish CDMO owned by Reig Jofre, explains the company’s twofold business model of developing and manufacturing…

5 Biotechs to Watch China October 2019

China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics.…

Cheney Mao – Chairman & CEO, Viva Biotech, China

Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO…